Table 1.

Studies assessing miRNAs expression in plasma among colorectal tumor patients and healthy controls

Ref.Author(s), yearStudy populationMethodsNormalization controlsmiR
CountryCases (stage I/II/III/IV)ControlAge mean (range)Tested miRs (No.)Significant miRs (No.)Difference between cases and controls (P)
15Pu et al., 2010China103 (7/38/40/18) CRC32 healthyCRC 58 (median; 39–84) Control 32 (median; 17–77)SYBR green qRT-PCR31miR-221↑P = 0.0021
16Huang et al., 2010China100 (27/25/38/10) CRCa59 healthyaCRC 61 (26–84)SYBR green qRT-PCRmiR-16122miR-29a↑P < 0.0001
37 advanced adenomasaAdenoma 55 (34–75)miR-92a↑P < 0.0001
Control 58 (27–81)miR-29a↑P < 0.0001
miR-92a↑P < 0.0001
17Ng et al., 2009China130 (6/35/39/50) CRCb75 healthybCRC 71 (42–91)Cancer microRNA array and SYBR green qRT-PCRRNU6B952miR-17–3p↑P < 0.0001
Control 69 (45–85)miR-92↑P < 0.0001
  • a3 miRs were selected from 12 miRs on a set of plasma samples (20 cases vs. 20 controls), then validated in 80 CRC, 37 advanced adenomas, and 39 healthy controls.

  • b5 miRs were selected from 95 miRs by comparing miRNA profiles from plasma of 5 CRC patients versus 5 age-matched healthy controls and tissues of 5 CRC patients versus 5 adjacent normal tissues with miRNA Array, then 2 miRs were seclected from the validation on a small set of plasma samples (35 cases vs. 20 controls) by qRT-PCR, then a large-scale validation on plasma samples (90 cases vs. 50 controls).